Raja Luthra

2.8k total citations
54 papers, 1.7k citations indexed

About

Raja Luthra is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Raja Luthra has authored 54 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 24 papers in Hematology and 15 papers in Oncology. Recurrent topics in Raja Luthra's work include Chronic Myeloid Leukemia Treatments (17 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Acute Myeloid Leukemia Research (12 papers). Raja Luthra is often cited by papers focused on Chronic Myeloid Leukemia Treatments (17 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Acute Myeloid Leukemia Research (12 papers). Raja Luthra collaborates with scholars based in United States, Malaysia and Italy. Raja Luthra's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Keyur P. Patel, Farhad Ravandi, Srđan Verstovšek, Patrick M. Lynch, Mark J. Routbort, Russell R. Broaddus, Guillermo Garcia‐Manero and Tapan M. Kadia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Raja Luthra

53 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raja Luthra United States 24 607 526 468 456 439 54 1.7k
Nicole Mentens Belgium 22 765 1.3× 449 0.9× 178 0.4× 766 1.7× 360 0.8× 33 2.4k
Joke W. Baars Netherlands 23 641 1.1× 935 1.8× 241 0.5× 348 0.8× 507 1.2× 52 2.4k
Ashish M. Ingle United States 24 308 0.5× 788 1.5× 348 0.7× 1.2k 2.7× 383 0.9× 36 2.5k
Thomas Melchardt Austria 23 247 0.4× 559 1.1× 160 0.3× 380 0.8× 486 1.1× 93 1.4k
Gisele W. B. Colleoni Brazil 21 432 0.7× 590 1.1× 165 0.4× 678 1.5× 152 0.3× 85 1.5k
María Eugenia Sarasquete Spain 26 837 1.4× 608 1.2× 456 1.0× 971 2.1× 401 0.9× 80 1.9k
Stefan Dirnhofer Switzerland 22 196 0.3× 539 1.0× 168 0.4× 367 0.8× 324 0.7× 89 1.6k
Dominique Leroux France 24 672 1.1× 841 1.6× 181 0.4× 880 1.9× 660 1.5× 74 2.4k
José María Sayagués Spain 23 294 0.5× 292 0.6× 216 0.5× 367 0.8× 231 0.5× 66 1.3k
Paola Casieri Italy 19 252 0.4× 624 1.2× 212 0.5× 389 0.9× 144 0.3× 43 1.5k

Countries citing papers authored by Raja Luthra

Since Specialization
Citations

This map shows the geographic impact of Raja Luthra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raja Luthra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raja Luthra more than expected).

Fields of papers citing papers by Raja Luthra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raja Luthra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raja Luthra. The network helps show where Raja Luthra may publish in the future.

Co-authorship network of co-authors of Raja Luthra

This figure shows the co-authorship network connecting the top 25 collaborators of Raja Luthra. A scholar is included among the top collaborators of Raja Luthra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raja Luthra. Raja Luthra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nair, Ranjit, Jingjing Liu, Chen Zhou, et al.. (2024). An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL. Blood. 144(Supplement 1). 455–455. 1 indexed citations
2.
Napolitano, Stefania, Aparna R. Parikh, Jason T. Henry, et al.. (2023). Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precision Oncology. 7(7). e2300228–e2300228. 1 indexed citations
3.
Montes‐Moreno, Santiago, Mark J. Routbort, Bedia A. Barkoh, et al.. (2018). Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS ONE. 13(9). e0204218–e0204218. 18 indexed citations
4.
Sarshekeh, Amir Mehrvarz, Shailesh Advani, Michael J. Overman, et al.. (2017). Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE. 12(3). e0173345–e0173345. 64 indexed citations
5.
Lou, Yanyan, Chad V. Pecot, Hai T. Tran, et al.. (2015). Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer. 17(2). e5–e11. 39 indexed citations
6.
Badar, Talha, Hagop M. Kantarjian, Graciela M. Nogueras‐González, et al.. (2015). Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology. 90(11). 1065–1070. 20 indexed citations
7.
Badar, Talha, Keyur P. Patel, Philip A. Thompson, et al.. (2015). Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39(12). 1367–1374. 39 indexed citations
8.
Jardim, Denis L., Chad Tang, Débora De Melo Gagliato, et al.. (2014). Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research. 20(24). 6336–6345. 65 indexed citations
9.
Jaso, Jesse, C. Cameron Yin, Ming Zhao, et al.. (2013). B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Modern Pathology. 27(3). 382–389. 8 indexed citations
10.
Jain, Preetesh, Hagop M. Kantarjian, Keyur P. Patel, et al.. (2013). MutatedNPM1in patients with acute myeloid leukemia in remission and relapse. Leukemia & lymphoma. 55(6). 1337–1344. 30 indexed citations
11.
Ohanian, Maro, Hagop M. Kantarjian, Alfonso Quintás‐Cardama, et al.. (2013). Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clinical Lymphoma Myeloma & Leukemia. 14(2). 155–162.e1. 34 indexed citations
12.
Luthra, Raja, Keyur P. Patel, Neelima G. Reddy, et al.. (2013). Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 99(3). 465–473. 124 indexed citations
13.
Kadia, Tapan M., Hagop M. Kantarjian, Steven M. Kornblau, et al.. (2012). Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 118(22). 5550–5559. 30 indexed citations
14.
Al‐Zaid, Tariq, Jeremy S. Ditelberg, Víctor G. Prieto, et al.. (2012). Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. Journal of Cutaneous Pathology. 39(5). 493–499. 23 indexed citations
15.
Daver, Naval, Paolo Strati, Elias Jabbour, et al.. (2012). FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. American Journal of Hematology. 88(1). 56–59. 82 indexed citations
16.
Borthakur, Gautam, Hagop M. Kantarjian, Keyur P. Patel, et al.. (2012). Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 118(23). 5819–5822. 13 indexed citations
17.
Verstovšek, Srđan, Jeffrey L. Jorgensen, Taghi Manshouri, et al.. (2008). Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Modern Pathology. 22(1). 50–57. 28 indexed citations
18.
Broaddus, Russell R., et al.. (2004). Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Modern Pathology. 17(8). 981–989. 57 indexed citations
19.
Jabbour, Elias, Hagop M. Kantarjian, Srđan Verstovšek, et al.. (2004). Imatinib Mesylate for Patients (pts) with Hypereosinophilic Syndrome (HES) and Systemic Mastocytosis (SM): A Phase II Trial.. Blood. 104(11). 4752–4752. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole Mentens Breakdown of academic impact, for papers by Joke W. Baars Breakdown of academic impact, for papers by Ashish M. Ingle Breakdown of academic impact, for papers by Thomas Melchardt Breakdown of academic impact, for papers by Gisele W. B. Colleoni Breakdown of academic impact, for papers by María Eugenia Sarasquete Breakdown of academic impact, for papers by Stefan Dirnhofer Breakdown of academic impact, for papers by Dominique Leroux Breakdown of academic impact, for papers by José María Sayagués Breakdown of academic impact, for papers by Paola Casieri
Rankless by CCL
2026